Wall St slips as uncertainty surrounds U.S. election
U.S. stocks dip as election nears, with Trump and Harris in a tight race and investors bracing for Fed policy news.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Democratic presidential candidate Kamala Harris campaigns in Michigan on Sunday while her Republican rival Donald Trump stops in three eastern battleground states just two days before elections
Democratic candidate Kamala Harris and Republican Donald Trump remain in a tight race in the country's seven battleground states
Spain is deploying 7,500 troops to its eastern region hit by deadly floods, where at least 217 people have died
AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
An analysis of U.S. health claims reveals that while GLP-1 drugs like Wegovy may aid weight loss, they significantly increase medical costs—rising to $18,507 annually—without reducing obesity-related health events, raising concerns for insurers and employers.
The CDC confirms bird flu in two Washington poultry workers and ruled out infections in Missouri healthcare staff.
UK government has confirmed that disposable vapes will be banned from sale starting June 2025
Germany has detected its first case of the new mpox variant, clade 1b, in a 33-year-old man.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment